Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells.
AffiliationCarcinogenesis Group and Experimental Radiation Oncology Group, Cancer Research Campaign, Paterson Institute for Cancer Research, Wilmslow Road, Manchester M20 4BX, UK.
MetadataShow full item record
AbstractThe strand transferase RAD51 is a component of the homologous recombination repair pathway. To examine the contribution of RAD51 to the genotoxic effects of ionising radiation, we have used a novel ribozyme strategy. A reporter gene vector was constructed so that expression of an inserted synthetic double-stranded ribozyme-encoding oligonucleotide would be under the control of the cytomegalovirus immediate-early gene enhancer/promoter system. The prostate tumour cell line LNCaP was transfected with this vector or a control vector, and a neomycin resistance gene on the vector was used to create geneticin-resistant stable cell lines. Three stable cell lines were shown by western blot analysis to have significant down-regulation of RAD51 to 20-50% of the levels expressed in control cell lines. All three cell lines had a similar increased sensitivity to gamma-irradiation by 70 and 40%, respectively, compared to normal and empty vector-transfected cells, corresponding to dose-modifying factors of approximately 2.0 and 1.5 in the mid-range of the dose-response curves. The amount of RAD51 protein in transfected cell lines was shown to strongly correlate with the alpha parameter obtained from fitted survival curves. These results highlight the importance of RAD51 in cellular responses to radiation and are the first to indicate the potential use of RAD51-targeted ribozyme minigenes in tumour radiosensitisation.
CitationRibozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells. 2001, 29 (7):1534-8 Nucleic Acids Res.
JournalNucleic Acids Research
- Coordinate alterations in the expression of BRCA1, BRCA2, p300, and Rad51 in response to genotoxic and other stresses in human prostate cancer cells.
- Authors: Yuan R, Fan S, Wang JA, Meng Q, Ma Y, Schreiber D, Goldberg ID, Rosen EM
- Issue date: 1999 Jun 15
- Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
- Authors: Dorai T, Olsson CA, Katz AE, Buttyan R
- Issue date: 1997 Sep 1
- Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines.
- Authors: Tekur S, Ho SM
- Issue date: 2002 Jan
- Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
- Authors: Latham JP, Searle PF, Mautner V, James ND
- Issue date: 2000 Jan 15
- Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair.
- Authors: Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, Bristow RG
- Issue date: 2010 Nov 1